-
Something wrong with this record ?
Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study
O. Zahornacký, Š. Porubčin, A. Rovňáková, P. Jarčuška, D. Semenovová, P. Kubalcová, E. Dorko, K. Rimárová
Language English Country Czech Republic
Document type Journal Article
Digital library NLK
Source
NLK
Free Medical Journals
from 2004
ProQuest Central
from 2009-03-01 to 6 months ago
Medline Complete (EBSCOhost)
from 2006-03-01 to 6 months ago
Nursing & Allied Health Database (ProQuest)
from 2009-03-01 to 6 months ago
Health & Medicine (ProQuest)
from 2009-03-01 to 6 months ago
Public Health Database (ProQuest)
from 2009-03-01 to 6 months ago
ROAD: Directory of Open Access Scholarly Resources
from 1993
PubMed
39832155
DOI
10.21101/cejph.a8398
Knihovny.cz E-resources
- MeSH
- Antiviral Agents * therapeutic use MeSH
- COVID-19 mortality epidemiology MeSH
- Cytidine * analogs & derivatives therapeutic use MeSH
- Adult MeSH
- COVID-19 Drug Treatment * MeSH
- Hospitalization statistics & numerical data MeSH
- Hydroxylamines therapeutic use MeSH
- Leucine therapeutic use analogs & derivatives MeSH
- Middle Aged MeSH
- Humans MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- SARS-CoV-2 MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors. METHODS: We conducted a single-centre, descriptive, retrospective study without a comparison group. RESULTS: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020). CONCLUSION: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25006810
- 003
- CZ-PrNML
- 005
- 20250403105209.0
- 007
- ta
- 008
- 250311s2024 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a8398 $2 doi
- 035 __
- $a (PubMed)39832155
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Zahornacký, Ondrej $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0241911
- 245 10
- $a Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study / $c O. Zahornacký, Š. Porubčin, A. Rovňáková, P. Jarčuška, D. Semenovová, P. Kubalcová, E. Dorko, K. Rimárová
- 520 9_
- $a OBJECTIVE: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors. METHODS: We conducted a single-centre, descriptive, retrospective study without a comparison group. RESULTS: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020). CONCLUSION: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rizikové faktory $7 D012307
- 650 12
- $a farmakoterapie COVID-19 $7 D000093485
- 650 12
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a cytidin $x analogy a deriváty $x terapeutické užití $7 D003562
- 650 _2
- $a hydroxylaminy $x terapeutické užití $7 D006898
- 650 _2
- $a COVID-19 $x mortalita $x epidemiologie $7 D000086382
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a hospitalizace $x statistika a číselné údaje $7 D006760
- 650 _2
- $a leucin $x terapeutické užití $x analogy a deriváty $7 D007930
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Porubčín, Štefan $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 _AN122180
- 700 1_
- $a Rovňáková, Alena $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0241883
- 700 1_
- $a Jarčuška, Pavol $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0073933
- 700 1_
- $a Semenovová, Dária $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 _AN122181
- 700 1_
- $a Kubalcová, Paulína $u Department of Radiology, AGEL Hospital, Levoca, Slovak Republic $7 _AN122099
- 700 1_
- $a Dorko, Erik $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0063738
- 700 1_
- $a Rimárová, Kvetoslava, $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $d 1958- $7 xx0224806
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 32, Suppl. (2024), s. 104-110
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39832155 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20250311 $b ABA008
- 991 __
- $a 20250403105204 $b ABA008
- 999 __
- $a ok $b bmc $g 2295224 $s 1243875
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 32 $c Suppl. $d 104-110 $e - $i 1210-7778 $m Central European journal of public health $n Cent Eur J Public Health $x MED00001083
- LZP __
- $b NLK116 $a Pubmed-20250311
